Clinical trial
A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients With Inflammatory Bowel Disease
NCT02566889 is registered in ClinicalTrials.gov with Janssen Scientific Affairs, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients With Inflammatory Bowel Disease
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- April 30, 2016
- Completion date
- July 31, 2019
- Enrollment
- 53 (actual)
- Sites
- 36
Conditions
As the registry lists them; a condition with its own page is linked.